Browsing Tag
oncology drug delivery
6 posts
How the Japan patent allowance could strengthen RenovoRx’s oncology platform valuation story
Could RenovoRx’s Japan patent strengthen the RNXT valuation story? Read what this means for growth, competition, and investor sentiment.
Avacta Group (AIM: AVCT) claims preCISION payload delivery shows structural advantages over ADCs as AVA6103 nears clinic
Avacta Group plc releases new data claiming preCISION delivery advantages over ADCs as AVA6103 prepares to enter clinical trials. Read more.
What continuous drug exposure could mean for immunomodulatory therapy in multiple myeloma
Can continuous lenalidomide exposure reshape immunomodulatory therapy economics? Explore the strategic stakes for Starton Therapeutics Inc.
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.